Zyrova 10 Tablet contains Rosuvastatin 10 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby decreasing cholesterol production in the liver and enhancing the clearance of LDL-C from the bloodstream. Zyrova 10 is prescribed as part of a comprehensive lipid management program including diet, exercise, and lifestyle modifications to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and the need for coronary revascularization in patients with atherosclerotic cardiovascular disease or multiple risk factors. The tablet is administered orally, typically once daily, with or without food. Dosage adjustments may be necessary based on individual patient response, renal function, and potential drug interactions. Common adverse effects include headache, myalgia, and gastrointestinal disturbances, while serious side effects such as myopathy and hepatotoxicity are rare but warrant monitoring. Zyrova 10 should be used under medical supervision with periodic assessment of lipid levels, liver enzymes, and muscle symptoms.